Trial Profile
Switching to duloxetine to ameliorate SSRI-induced sexual dysfunction
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Duloxetine (Primary)
- Indications Depressive disorders; Dysthymic disorder
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 05 Jun 2012 Actual patient number added 3 according to ClinicalTrials.gov.
- 15 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 25 Nov 2006 New trial record.